666 related articles for article (PubMed ID: 33178841)
1. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
2. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.
Joshi M; Ansell SM
J Immunol Res; 2020; 2020():8820377. PubMed ID: 33294467
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
4. Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
Barroso-Sousa R; Tolaney SM
Curr Treat Options Oncol; 2020 Jun; 21(7):59. PubMed ID: 32556894
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials.
Akhbariyoon H; Azizpour Y; Esfahani MF; Firoozabad MSM; Rad MR; Esfahani KS; Khoshavi N; Karimi N; Shirinisaz A; Abedi F; Rad MR; Sharifi P
Clin Immunol; 2021 Nov; 232():108873. PubMed ID: 34688855
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
[TBL] [Abstract][Full Text] [Related]
8. Genetically Engineered Mouse Models Support a Major Role of Immune Checkpoint-Dependent Immunosurveillance Escape in B-Cell Lymphomas.
Lemasson Q; Akil H; Feuillard J; Vincent-Fabert C
Front Immunol; 2021; 12():669964. PubMed ID: 34113345
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
Hu B; Jacobs R; Ghosh N
Curr Hematol Malig Rep; 2018 Dec; 13(6):543-554. PubMed ID: 30338457
[TBL] [Abstract][Full Text] [Related]
10. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.
Dermime S; Merhi M; Merghoub T
Front Immunol; 2021; 12():781872. PubMed ID: 34745152
[No Abstract] [Full Text] [Related]
12. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
Zhang Q; Tang L; Zhou Y; He W; Li W
Front Immunol; 2021; 12():663986. PubMed ID: 34122422
[TBL] [Abstract][Full Text] [Related]
14. The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series).
Sukari A; Kukreja G; Nagasaka M; Shukairy MK; Yoo G; Lin HS; Hotaling J; Kim H
Oral Oncol; 2020 Oct; 109():104744. PubMed ID: 32402656
[TBL] [Abstract][Full Text] [Related]
15. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.
Xu Y; Fu Y; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():2023. PubMed ID: 33123120
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
Merryman RW; Armand P; Wright KT; Rodig SJ
Blood Adv; 2017 Dec; 1(26):2643-2654. PubMed ID: 29296917
[TBL] [Abstract][Full Text] [Related]
17. Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma.
Veldman J; Visser L; Berg AVD; Diepstra A
Cancer Treat Rev; 2020 Jan; 82():101931. PubMed ID: 31756590
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
19. Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma.
Zeng FL; Chen JF
Technol Cancer Res Treat; 2021; 20():15330338211039952. PubMed ID: 34528830
[TBL] [Abstract][Full Text] [Related]
20. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
Zhang N; Wei L; Ye M; Kang C; You H
Front Immunol; 2020; 11():592612. PubMed ID: 33329578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]